Business
Notice of Interim Results and Presentation
Notice of Interim Results and Presentation.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n26 January 2024\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \nNotice of Interim Results and Presentation\n \nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, will announce its interim results for the six months ended 31 October 2023 on Tuesday 30 January 2024.\n \nProfessor Lindy Durrant, Chief Executive Officer, and Sath Nirmalananthan, Chief Financial Officer, will host a live webcast and Q&A session for analysts and investors at 14:00 GMT. If you would like to join the webcast, please follow this link: https://www.lsegissuerservices.com/spark/ScancellHoldings/events/f581274b-146c-4a89-af15-05bcae874775\n \nA replay of the webcast will be made available shortly afterwards.\n \nPlease contact ICR Consilium for further details.\n \nA copy of the presentation will also be made available on the Company's news section following the presentation.\n \n-ENDS-\n \n\n\n\n\nFor further information, please contact:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nScancell Holdings plc\n\n\n+44 (0) 20 3709 5700\n\n\n\n\nProfessor Lindy Durrant, CEO\nDr Jean-Michel Cosséry, Non-Executive Chairman\n \n\n\n\n\n\n\n\nStifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)\n\n\n+44 (0) 20 7710 7600\n\n\n\n\nNicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)\n\n\n \n\n\n\n\nNick Adams/Nick Harland (Corporate Broking)\n \n\n\n \n\n\n\n\nWG Partners LLP (Joint Broker)\n \nDavid Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby \n \n\n\n+44 (0) 20 3705 9330\n\n\n\n\nPanmure Gordon (UK) Limited (Joint Broker)\n\n\n+44 (0) 20 7886 2500\n\n\n\n\nFreddy Crossley/Emma Earl (Corporate Finance)\n\n\n \n\n\n\n\nRupert Dearden (Corporate Broking)\n\n\n \n\n\n\n\n \n\n\n\n\nICR Consilium\n\n\n+44 (0) 20 3709 5700\n\n\n\n\nMary-Jane Elliott/Matthew Neal/Chris Welsh\n\n\[email protected]\n \n\n\n\n\n \nAbout Scancell\n \nScancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Compa...